Lantheus Holdings Beheer

Beheer criteriumcontroles 2/4

De CEO Lantheus Holdings is Brian Markison, benoemd in Mar2024, heeft een ambtstermijn van minder dan een jaar. bezit rechtstreeks 0.025% van de aandelen van het bedrijf, ter waarde € 1.32M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 1.7 jaar en 6.8 jaar.

Belangrijke informatie

Brian Markison

Algemeen directeur

US$539.1k

Totale compensatie

Percentage CEO-salaris	n/a
Dienstverband CEO	less than a year
Eigendom CEO	0.02%
Management gemiddelde ambtstermijn	1.7yrs
Gemiddelde ambtstermijn bestuur	6.8yrs

Recente managementupdates

Recent updates

CEO

Brian Markison (65 yo)

less than a year

Tenure

US$539,112

Compensatie

Mr. Brian A. Markison has served as Chairman of the Board and Chief Executive Officer of Osmotica Pharmaceutical Corp. since 2016. Mr. Markison had been an Operating Executive and Healthcare Industry Execu...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Brian Markison	CEO & Director	less than a year	US$539.11k	0.025% € 1.3m
Paul Blanchfield	President	1.7yrs	US$5.31m	0.14% € 7.6m
Robert Marshall	CFO & Treasurer	6.2yrs	US$4.33m	0.16% € 8.7m
Jean-Claude Provost	Chief Science Officer	less than a year	US$3.08m	0.0083% € 440.5k
Daniel Niedzwiecki	Chief Administrative Officer	3.8yrs	US$3.12m	0.11% € 6.0m
Kimberly Brown	Chief Accounting Officer	less than a year	geen gegevens	geen gegevens
Dorothy Barr	Senior Vice President of Manufacturing & Technical Operations	2.4yrs	geen gegevens	geen gegevens
Lee Howe	Chief Information Officer	less than a year	geen gegevens	geen gegevens
Mark Kinarney	Senior Director of Investor Relations	no data	geen gegevens	geen gegevens
Linda Lennox	VP of Corporate Communications & Chief of Staff	4.3yrs	geen gegevens	geen gegevens
Jamie Spaeth	Chief People Officer	less than a year	geen gegevens	geen gegevens
Carol Walker	Senior Vice President of Quality	6.6yrs	geen gegevens	geen gegevens

1.7yrs

Gemiddelde duur

57yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van 0L8 wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 1.7 jaar), wat duidt op een nieuw team.

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Brian Markison	CEO & Director	12.2yrs	US$539.11k	0.025% € 1.3m
Samuel Leno	Independent Director	12.5yrs	US$493.31k	0.087% € 4.7m
Julie Eastland	Independent Director	less than a year	geen gegevens	0.0019% € 103.0k
James Thrall	Independent Director	6.8yrs	US$483.39k	0.045% € 2.4m
Mary Heino	Chairman of the Board	9.3yrs	US$12.58m	0.88% € 46.9m
Minnie Baylor-Henry	Independent Director	2.7yrs	US$477.89k	0.0043% € 231.2k
Gérard Ber	Independent Director	4.4yrs	US$470.81k	0.027% € 1.4m
Julie McHugh	Lead Independent Director	7.8yrs	US$479.11k	0.034% € 1.8m
Gary John Pruden	Independent Director	6.8yrs	US$493.31k	0.029% € 1.6m
Heinz Mausli	Independent Director	4.4yrs	US$480.00k	0.036% € 1.9m

6.8yrs

Gemiddelde duur

64.5yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van 0L8 wordt beschouwd als ervaren (gemiddelde ambtstermijn 6.8 jaar).

Lantheus Holdings Beheer

Beheer criteriumcontroles 2/4

Belangrijke informatie

Recente managementupdates

Lantheus Holdings, Inc. Appoints Julie Eastland as Board of Directors

Lantheus Holdings, Inc. Appoints Jamie Spaeth as Chief People Officer

Lantheus Holdings, Inc. Announces Management Appointments, Effective May 28, 2024

Lantheus Holdings, Inc., Annual General Meeting, Apr 25, 2024

Lantheus Holdings, Inc. Announces CEO Changes, Effective March 1, 2024

Lantheus Holdings, Inc. Elevates Robert J. Marshall, Jr. as Treasurer

Recent updates

Investor sentiment deteriorates as stock falls 26%

Third quarter 2024 earnings released: EPS: US$1.89 (vs US$1.93 in 3Q 2023)

Lantheus Holdings, Inc. Raises Earnings Guidance for the Full Year 2024

Lantheus Holdings, Inc. to Report Q3, 2024 Results on Nov 06, 2024

New major risk - Share price stability

Lantheus Presents Results from the Primary Analysis of Phase 3 Pivotal SPLASH Trial in PSMA-Positive Metastatic Castration-Resistant Prostate Cancer During ESMO Congress 2024

Lantheus Holdings, Inc. Appoints Julie Eastland as Board of Directors

Second quarter 2024 earnings released: EPS: US$0.90 (vs US$1.38 in 2Q 2023)

Lantheus Holdings, Inc. Maintains Revenue Guidance for the Full Year of 2024

Lantheus Holdings, Inc. to Report Q2, 2024 Results on Jul 31, 2024

Investor sentiment improves as stock rises 33%

Lantheus Holdings, Inc. Appoints Jamie Spaeth as Chief People Officer

Lantheus Holdings, Inc. Announces Management Appointments, Effective May 28, 2024

Lantheus Holdings, Inc. Revises Revenue Guidance for the Full Fiscal Year 202

First quarter 2024 earnings released: EPS: US$1.91 (vs US$0.041 loss in 1Q 2023)

Lantheus Holdings, Inc., Annual General Meeting, Apr 25, 2024

Lantheus Holdings, Inc. Announces the FDA Approval of Definity (Perflutren Lipid Microsphere) for Pediatric Patients

Full year 2023 earnings released: EPS: US$4.79 (vs US$0.41 in FY 2022)

Lantheus Holdings, Inc. Provides Earnings Guidance for the First Quarter and Full Year 2024

Lantheus Holdings, Inc. Announces CEO Changes, Effective March 1, 2024

Lantheus Holdings, Inc. Announces Acceptance of its First-to-File ANDA for Generic Lutathera (Lutetium Lu 177 Dotatate)

Lantheus Holdings, Inc. Provides Revenue Guidance for Its Fiscal Year Ended December 31, 2023

Now 31% undervalued after recent price drop

Lantheus Holdings, Inc. and POINT Biopharma Global Inc. Announce Positive Topline Results from Pivotal Splash Trial in Metastatic Castration-Resistant Prostate Cancer

Now 24% undervalued after recent price drop

New major risk - Revenue and earnings growth

Lantheus Holdings, Inc. Updates Earnings Guidance for the Full Year 2023

Third quarter 2023 earnings released: EPS: US$1.88 (vs US$0.89 in 3Q 2022)

Lantheus Holdings, Inc. Elevates Robert J. Marshall, Jr. as Treasurer

New minor risk - Earnings quality

Lantheus Holdings, Inc. Provides Revenue Guidance for the Third Quarter of Fiscal Year 2023

New minor risk - Share price stability

Second quarter 2023 earnings released: EPS: US$1.38 (vs US$0.63 in 2Q 2022)

Ratio Therapeutics Inc. In Collaboration with Lantheus and PharmaLogic, Announce First Patient Dosed in Phase I Study Evaluating a Novel FAP-Targeted Radiopharmaceutical for Pet Imaging

Insufficient new directors

Lantheus Holdings, Inc. Revises Revenue Guidance for the Fiscal Year 2023

First quarter 2023 earnings released: US$0.041 loss per share (vs US$0.63 profit in 1Q 2022)

Full year 2022 earnings released: EPS: US$0.41 (vs US$1.06 loss in FY 2021)

Investor sentiment improves as stock rises 16%

Lantheus Holdings, Inc. to Report Q4, 2022 Results on Feb 23, 2023

Lantheus Holdings, Inc. Presents Data Reinforcing Real-World Clinical Utility of Piflufolastat F 18 PET Scanning in Men with Recurrent Prostate Cancer and Low PSA Levels

Lantheus to Present Piflufolastat F 18 Data at the 2023 American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium

Lantheus Holdings, Inc. (NasdaqGM:LNTH) acquired Cerveau Technologies, Inc.

Lantheus Holdings, Inc. Appoints Amanda Morgan as Senior Vice President, Commercial

Lantheus Announces the Approval of DEFINITY® (Perflutren Lipid Microsphere) by China’s NMPA

Investor sentiment deteriorated over the past week

Third quarter 2022 earnings released: EPS: US$0.89 (vs US$0.20 loss in 3Q 2021)

Lantheus Holdings, Inc. Provides Revenue Guidance for the Fourth Quarter 2022

GE Healthcare and Lantheus Holdings Inc Announces Phase III Clinical Trial Finds [¹8F]flurpiridaz PET Radiotracer Could Improve Detection of Coronary Artery Disease

Second quarter 2022 earnings released: EPS: US$0.63 (vs US$0.40 loss in 2Q 2021)

Lantheus Holdings, Inc. Updates Earnings Guidance for the Full Year 2022

Lantheus Holdings, Inc.(NasdaqGM:LNTH) dropped from Russell Microcap Index

Lantheus Holdings, Inc. Announces Executive Changes

Lantheus’ PYLARIFY AI™ Platform Demonstrates Higher Efficiency and Consistency While Maintaining Accuracy for Assessment of PSMA Imaging in Prostate Cancer

Lantheus Holdings, Inc. Presents Results from a PYLARIFY AI™ Study at the American Urological Association (AUA) Annual Meeting

Independent Director recently sold €71k worth of stock

Lantheus Holdings, Inc. Announces First Patient Dosed in Phase 2 Clinical Trial of NM-01 to Monitor PD-L1 Expression in Non-Small Cell Lung Cancer Patients

Lantheus Holdings, Inc. Revises Earnings Guidance for the Full Year of Fiscal 2022

First quarter 2022 earnings released: EPS: US$0.63 (vs US$0.13 in 1Q 2021)

Lantheus Holdings, Inc. Appoints Jean-Claude Provost as Interim Chief Medical Officer

Principal Accounting Officer recently sold €104k worth of stock

Lantheus Announces Appointment of Minnie Baylor-Henry as New Board Member

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

Lantheus Holdings, Inc. Reports Impairment of Long-Lived Assets for the Fourth Quarter Ended December 31, 2021

Lantheus Holdings, Inc. Receives U.S. FDA Approval of New Manufacturing Facility

Lantheus Announces PYLARIFY AI™ is Now Available

Lantheus Holdings, Inc. Announces CMS Grants Transitional Pass-Through Payment for PYLARIFY® (piflufolastat F 18) Injection, Effective January 1, 2022

Third quarter 2021 earnings released: US$0.20 loss per share (vs US$0.096 loss in 3Q 2020)

Lantheus Announces Addition of PSMA Pet Imaging Agent to the National Comprehensive Cancer Network® (Nccn) Guidelines for Prostate Cancer